X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare immune disorders. Its lead approved product is XOLREMDI (mavorixafor), an oral medicine used in WHIM syndrome, and the company also advances mavorixafor in additional neutropenic and immunology indications.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCommercial sale of XOLREMDI for WHIM syndrome in the U.S. and other approved markets.
Upfront, milestone, and license payments from regional commercialization partners.
Drug supply and related commercial manufacturing services under partner agreements.
Tuotteet
Raportoitu · osuus liikevaihdosta- License and Other Revenue81,4 %
- Products18,6 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
X4 sells primarily to specialty pharmacy and distribution channels that dispense XOLREMDI to patients prescribed by physicians. Its commercial model also depends on healthcare providers, rare-disease specialists, patient advocacy groups, and third-party payors that influence diagnosis, access, reimbursement, and ongoing use.
Buys and dispenses approved product to patients after physician prescription; critical for U.S. access.
Prescribe XOLREMDI and drive diagnosis, treatment initiation, and patient follow-up.
Reimburse treatment and influence patient access through coverage, rebates, and utilization controls.
License and distribute the product in ex-U.S. territories under local market agreements.
Support disease awareness and early diagnosis, helping expand the treated patient pool.
Strategia
X4’s strategy centers on building the commercial footprint of XOLREMDI while expanding the addressable market for mavorixafor through regulatory approvals and partner-led launches. The company uses licensing and distribution agreements to extend reach outside the U.S. without building a large direct international sales infrastructure.
The approved product is the main near-term revenue engine and depends on diagnosis and access.
Licensing reduces the need for direct international infrastructure while broadening market reach.
Additional indications can enlarge the patient pool and diversify dependence on one rare disease.
Maantiede
The company is headquartered in the United States and currently commercializes XOLREMDI in the U.S. through specialty pharmacy distribution. It also pursues ex-U.S. commercialization through regional partners, including the European Economic Area, Switzerland, the United Kingdom, Australia, New Zealand, and selected Middle East and North African countries.
Riskit
X4 is exposed to the risks typical of a small commercial-stage biotech: dependence on a single approved product, uncertainty around reimbursement and patient access, and heavy reliance on clinical and regulatory success for future growth. It also faces financing risk, supply-chain concentration, and healthcare compliance risk because commercialization depends on third-party manufacturers, specialty pharmacies, and payor relationships.
- Product concentrationVaikutus: KorkeaTodennäköisyys: Korkea
A large share of value depends on XOLREMDI and mavorixafor-related programs.
Kohdistuu: Single approved product and one core molecule
- Need for additional capitalVaikutus: KorkeaTodennäköisyys: Korkea
Commercial launch and clinical development consume cash before sustained profitability.
Kohdistuu - Clinical and development executionVaikutus: KorkeaTodennäköisyys: Korkea
Future growth depends on successful trials and regulatory approvals in new indications.
Kohdistuu: Phase 3 and other development programs
- Supply chain concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on single-source suppliers for active drug and finished capsules.
Kohdistuu: Manufacturing and commercial supply
- Regulatory and healthcare complianceVaikutus: KeskitasoTodennäköisyys: Matala
Pricing, rebates, patient support, and promotion are constrained by healthcare laws.
Kohdistuu: U.S. and foreign commercialization
Kirjanpito
Harkinnanvaraiset erätUpfront license fees, milestones, and services must be allocated across obligations.
Vaikutus: Can create lumpy quarterly revenue and timing differences
Rebates, co-pay assistance, distributor discounts, and returns reduce reported sales.
Vaikutus: Affects gross-to-net deductions and comparability across periods
Cost of revenue includes royalty obligations tied to license and sublicense income.
Vaikutus: Influences reported product margin and operating leverage
Amortization related to prior license milestones flows through cost of revenue.
Vaikutus: Can materially affect gross profit presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
XBiotech Inc.
XBIT · Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
KPTI · Pharmaceutical Preparations
C4 Therapeutics, Inc.
CCCC · Biological Products, (No Diagnostic Substances)
Xencor Inc
XNCR · Pharmaceutical Preparations
Palvella Therapeutics, Inc
PVLA · Pharmaceutical Preparations
Palvella Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare genetic skin and vascular disorders.
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Päivitetty: 24.9.2026